Volume : 12, Issue : 03, March – 2025
Title:
AN OVERVIEW OF ADVERSE DRUG REACTION (ADR)
Authors :
Mr. Mayur S.Gulhane, Dr. Swati P.Deshmukh
Abstract :
Adverse Drug Reactions (ADRs) continue to be a critical issue within healthcare systems worldwide. ADRs occur when an unintended and harmful reaction arises from the administration of a drug at normal doses. These reactions can range from mild to life-threatening and contribute significantly to patient morbidity, prolonged hospital stays, and, in severe cases, death. Despite extensive drug trials and safety testing prior to market release, ADRs remain an inevitable aspect of clinical treatment due to factors such as genetic variability, drug interactions, patient age, underlying diseases, and non-compliance with prescribed treatments.
Efforts have been made globally to mitigate the risks associated with ADRs, primarily through robust pharmacovigilance systems that monitor and report ADR incidents. Regulatory authorities like the FDA (U.S.), EMA (Europe), and others play a pivotal role in ensuring drug safety through post-marketing surveillance. Furthermore, ADR reporting systems have been established to encourage healthcare providers, pharmaceutical companies, and patients to report any adverse effects, which allows for continuous monitoring and evaluation of drug safety.
However, underreporting remains a challenge in many countries, largely due to a lack of awareness among healthcare professionals or insufficient infrastructure to collect data. Improving the accuracy and rate of ADR reporting can significantly reduce the risks associated with drug therapies and improve overall patient care.
Cite This Article:
Please cite this article in press Mayur S.Gulhane et al., An Overview Of Adverse Drug Reaction (ADR)., Indo Am. J. P. Sci, 2025; 12(05)..
Number of Downloads : 10
References:
1. Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. The Lancet, 356(9237), 1255-1259
2. Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA, 279(15), 1200-1205.
3. Pirmohamed, M., et al. (2004). Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. BMJ, 329(7456), 15-19.
4. Nebeker, J. R., Barach, P., & Samore, M. H. (2004). Clarifying adverse drug events: A clinician’s guide to terminology, documentation, and reporting. Annals of Internal Medicine, 140(10), 795-801.
5. Leape, L. L., & Berwick, D. M. (2005). Five years after To Err Is Human: What have we learned? JAMA, 293(19), 2384-2390.
6. Montané, E., & Santesmases, J. (2020). Adverse drug reactions. Medical Clinics of North America, 104(5), 865-878.
7. Moore, N., et al. (1998). Frequency and cost of serious adverse drug reactions in a department of general medicine. The Lancet, 351(9110), 1970-1973.
8. Hughes, D., et al. (2002). Cost of adverse drug reactions in the NHS hospitals: A multicentre retrospective study. Drug Safety, 25(8), 627-635.
9. Davies, E. C., et al. (2009). Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLOS ONE, 4(2), e4439.
10. Wiffen, P., Gill, M., Edwards, J., & Moore, A. (2002). Adverse drug reactions in hospital patients. British Journal of Clinical Pharmacology, 52(2), 113-117.
11. Kohn, L. T., Corrigan, J. M., & Donaldson, M. S. (Eds.). (2000). To Err Is Human: Building a Safer Health System. National Academies Press.
12. Pirmohamed, M., et al. (1998). Adverse drug reactions. British Medical Journal, 316(7140), 1295-1298.
13. Aronson, J. K., & Ferner, R. E. (2005). Clarification of terminology in drug safety. Drug Safety, 28(10), 851-870
14. WHO. (2002). The Importance of Pharmacovigilance – Safety Monitoring of Medicinal Products. World Health Organization.
15. Wu, T. Y., et al. (2010). Adverse drug reactions in the elderly: Predictors and prevention. British Journal of Clinical Pharmacology, 70(5), 515-521.
16. Hall, K. W., & Vermeulen, L. C. (2001). The role of computerized physician order entry systems in facilitating medication errors. Archives of Internal Medicine, 161(8), 1089-1097.
17. Gagne, J. J., et al. (2012). Pharmacovigilance: Advances in detection of adverse drug reactions. Current Epidemiology Reports, 1(3), 190-197.
18. Platt, R., et al. (2018). Pharmacovigilance in the era of big data. Drug Safety, 41(9), 1013-1020
19. Harpaz, R., et al. (2012). Data mining for adverse drug events. Nature Reviews Drug Discovery, 11(6), 518-528.
20. Curtis, L. H., et al. (2008). Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. American Journal of Medicine, 121(8), 657-663.
21. Stausberg, J., et al. (2014). Adverse events and adverse drug reactions in hospital: Frequency, impact, and prevention. Drug Safety, 37(9), 835-847.
22. Giardina, C., et al. (2018). Adverse drug reactions in hospitalized patients: Results from the Italian Pharmacovigilance Network. Frontiers in Pharmacology, 9, 350.
23. Giardina, C., & Cutroneo, P. (2018). Clinical and economic burden of adverse drug reactions. Journal of Pharmacovigilance, 6, 1000271.
24. Riedl, M. A., & Casillas, A. M. (2003). Adverse drug reactions: Types and treatment options. American Family Physician, 68(9), 1781-1790.
25. Gandhi, T. K., et al. (2003). Adverse drug events in ambulatory care. The New England Journal of Medicine, 348(16), 1556-1564.
26. Leendertse, A. J., et al. (2010). Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study. The International Journal of Clinical Pharmacy, 32(6), 618-625.
27. Herxheimer, A., & Crombie, I. K. (2003). Adverse drug reactions. The BMJ, 306(6880), 1498-1499.
28. Davies, E. C., et al. (2007). Emergency hospital admissions related to adverse drug reactions: A prospective analysis. Drug Safety, 30(8), 705-711.
29. Sheikh, A., et al. (2008). Adverse drug reactions in primary care. The Lancet, 372(9653), 1975-1976.
30. Becker, M. L., et al. (2007). Hospitalisations and emergency department visits due to drug-drug interactions: A literature review. Pharmacoepidemiology and Drug Safety, 16(6), 641-651.
These references can serve as a foundation for research, understanding ADR mechanisms, exploring case studies, or considering future directions in managing ADRs.